Seems similar to the story of durva + olaparib in #ProstateCancer investigated @theNCI led by @FatimaKarzai @billdahutmd #immunotherapy https://t.co/oqR20gHsBZ
遺伝子変異が、免疫療法への効果にも関わる、、、犬でも、去勢に反応しないのもいるもんなー。 いやぁ。深い。 https://t.co/StYeytz7Vv
@SKCCDirector Great pt to bring knowledge from multiple cancers to better understand the impact of individual DDR aberrations! Shouldn't give up yet on PARP in #bladdercancer noting some success in #prostatecancer for combo w #immunohterapy. #Worktodo! @AS
RT @gulleyj1: Interesting paper on PARP inhibitor and PDL1 inhibitor in #ProstateCancer showing activity. I https://t.co/Y39SYaDyYb #Target…
RT @gulleyj1: Interesting paper on PARP inhibitor and PDL1 inhibitor in #ProstateCancer showing activity. I https://t.co/Y39SYaDyYb #Target…
RT @gulleyj1: Interesting paper on PARP inhibitor and PDL1 inhibitor in #ProstateCancer showing activity. I https://t.co/Y39SYaDyYb #Target…
RT @gulleyj1: Interesting paper on PARP inhibitor and PDL1 inhibitor in #ProstateCancer showing activity. I https://t.co/Y39SYaDyYb #Target…
RT @gulleyj1: Interesting paper on PARP inhibitor and PDL1 inhibitor in #ProstateCancer showing activity. I https://t.co/Y39SYaDyYb #Target…
RT @gulleyj1: Interesting paper on PARP inhibitor and PDL1 inhibitor in #ProstateCancer showing activity. I https://t.co/Y39SYaDyYb #Target…
RT @gulleyj1: Interesting paper on PARP inhibitor and PDL1 inhibitor in #ProstateCancer showing activity. I https://t.co/Y39SYaDyYb #Target…
RT @gulleyj1: Interesting paper on PARP inhibitor and PDL1 inhibitor in #ProstateCancer showing activity. I https://t.co/Y39SYaDyYb #Target…
RT @gulleyj1: Interesting paper on PARP inhibitor and PDL1 inhibitor in #ProstateCancer showing activity. I https://t.co/Y39SYaDyYb #Target…
RT @gulleyj1: Interesting paper on PARP inhibitor and PDL1 inhibitor in #ProstateCancer showing activity. I https://t.co/Y39SYaDyYb #Target…
RT @gulleyj1: Interesting paper on PARP inhibitor and PDL1 inhibitor in #ProstateCancer showing activity. I https://t.co/Y39SYaDyYb #Target…
Interesting paper on PARP inhibitor and PDL1 inhibitor in #ProstateCancer showing activity. I https://t.co/Y39SYaDyYb #Targets19 https://t.co/yjRtuNm82L
Looking at efficacy of checkpoint blockade for enzalutamide (or apalutamide) resistant prostate cancer. So far found: 20-25% response rate to nivo: https://t.co/U5jGfnYerA ~50% response rate to durva + olaparib: https://t.co/VlMlHiRtru Any others? #o
RT @gulleyj1: The PARPi + PDXi story is also told in another #immunotherapy resistant tumor, #ProstateCancer. Read this @theNCI study here:…
RT @gulleyj1: The PARPi + PDXi story is also told in another #immunotherapy resistant tumor, #ProstateCancer. Read this @theNCI study here:…
RT @gulleyj1: The PARPi + PDXi story is also told in another #immunotherapy resistant tumor, #ProstateCancer. Read this @theNCI study here:…
RT @gulleyj1: The PARPi + PDXi story is also told in another #immunotherapy resistant tumor, #ProstateCancer. Read this @theNCI study here:…
RT @gulleyj1: The PARPi + PDXi story is also told in another #immunotherapy resistant tumor, #ProstateCancer. Read this @theNCI study here:…
""CONCLUSIONS: Durvalumab plus olaparib has acceptable toxicity, and the combination demonstrates efficacy, particularly in men with DDR abnormalities. https://t.co/EsA6i9qGgh
The PARPi + PDXi story is also told in another #immunotherapy resistant tumor, #ProstateCancer. Read this @theNCI study here: https://t.co/pxpfvwNqMy @sitcancer #JITC #ImmunoOnc19 https://t.co/v3LITIARl4
.@FatimaKarzai @NCIBillDahut @gulleyj1 @vanderweelemd @mbilusic @rdittamore
RT @sitcancer: #JITC Research: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and with…
PARP !
RT @sitcancer: #JITC Research: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and with…
RT @sitcancer: #JITC Research: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and with…
#JITC Research: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations https://t.co/GYaYSPn5Xb https://t.co/cT9oq61z21
#JITC Research: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations https://t.co/GYaYSPn5Xb https://t.co/IpC1GjC1ka
RT @sitcancer: #JITC Research: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and with…
RT @Aiims1742: Interesting paper from @nciccr_gmb @gulleyj1 & colleagues. Small single arm study but suggests BRCA or other DNA repair mut…
RT @sitcancer: #JITC Research: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and with…
RT @Aiims1742: Interesting paper from @nciccr_gmb @gulleyj1 & colleagues. Small single arm study but suggests BRCA or other DNA repair mut…
Congrats @FatimaKarzai @NCIBillDahut @gulleyj1 @Dr_RaviMadan @mbilusic
RT @Aiims1742: Interesting paper from @nciccr_gmb @gulleyj1 & colleagues. Small single arm study but suggests BRCA or other DNA repair mut…
RT @Aiims1742: Interesting paper from @nciccr_gmb @gulleyj1 & colleagues. Small single arm study but suggests BRCA or other DNA repair mut…
Interesting paper from @nciccr_gmb @gulleyj1 & colleagues. Small single arm study but suggests BRCA or other DNA repair mutations might facilitate PARPinh + #immunotherapy responses. This is now being evaluated in BRCA mutant #PancreaticCancer as well
#JITC Research: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations https://t.co/GYaYSPn5Xb https://t.co/GEga7VcEW2
RT @NCIResearchCtr: Latest #CCRAdvance from @NCIBillDahut and team! #ProstateCancer https://t.co/SOZpjdYDGO
RT @DrGattiMays: Nice work from the GMB on PD-L1 and PARPi in prostate cancer. @FatimaKarzai @gulleyj1 @Dr_RaviMadan @mbilusic @NCIResea…
RT @NCIResearchCtr: Latest #CCRAdvance from @NCIBillDahut and team! #ProstateCancer https://t.co/SOZpjdYDGO
Latest #CCRAdvance from @NCIBillDahut and team! #ProstateCancer
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @drleighellis: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damag…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @DrGattiMays: Nice work from the GMB on PD-L1 and PARPi in prostate cancer. @FatimaKarzai @gulleyj1 @Dr_RaviMadan @mbilusic @NCIResea…
RT @sitcancer: New #JITC Research: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and…
RT @NCICCR_MOS: Interesting clinical signal for PARPi + PDL1i in heavily pretreated metastatic castration resistant prostate cancer from @N…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @nciccr_gmb: Great to see this manuscript by @FatimaKarzai @NCIBillDahut @gulleyj1 @Dr_RaviMadan @mbilusic and other @NCIResearchCtr Gen…
Nice work from the GMB on PD-L1 and PARPi in prostate cancer. @FatimaKarzai @gulleyj1 @Dr_RaviMadan @mbilusic @NCIResearchCtr
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @drleighellis: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damag…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @drleighellis: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damag…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
The combination of PARP Inhibitors with immunotherapy is an exciting option in the treatment of prostate cancer! I look forward to further data in this space!
RT @drleighellis: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damag…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
Interesting clinical signal for PARPi + PDL1i in heavily pretreated metastatic castration resistant prostate cancer from @NCIResearchCtr researchers.
RT @DrPhilKantoff: Provocative study by @NCIBillDahut and colleagues. https://t.co/J2Rpe0gezj
RT @drleighellis: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damag…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @drleighellis: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damag…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @drleighellis: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damag…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @drleighellis: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damag…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @DrPhilKantoff: Provocative study by @NCIBillDahut and colleagues. https://t.co/J2Rpe0gezj
RT @nciccr_gmb: Great to see this manuscript by @FatimaKarzai @NCIBillDahut @gulleyj1 @Dr_RaviMadan @mbilusic and other @NCIResearchCtr Gen…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @drleighellis: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damag…
RT @DrPhilKantoff: Provocative study by @NCIBillDahut and colleagues. https://t.co/J2Rpe0gezj
Provocative study by @NCIBillDahut and colleagues.
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations | Journal for ImmunoTherapy of Cancer | Full Text https://t.co/TqsZM8FHsc
RT @nciccr_gmb: Great to see this manuscript by @FatimaKarzai @NCIBillDahut @gulleyj1 @Dr_RaviMadan @mbilusic and other @NCIResearchCtr Gen…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @nciccr_gmb: Great to see this manuscript by @FatimaKarzai @NCIBillDahut @gulleyj1 @Dr_RaviMadan @mbilusic and other @NCIResearchCtr Gen…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
RT @nciccr_gmb: Great to see this manuscript by @FatimaKarzai @NCIBillDahut @gulleyj1 @Dr_RaviMadan @mbilusic and other @NCIResearchCtr Gen…
RT @gulleyj1: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage re…
Great to see this manuscript by @FatimaKarzai @NCIBillDahut @gulleyj1 @Dr_RaviMadan @mbilusic and other @NCIResearchCtr Genitourinary Malignancies Branch investigators. @PCF_Science
Congratulations @FatimaKarzai ! @PCF_Science
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations https://t.co/EHhKWZM2m6
RT @sitcancer: New #JITC Research: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and…
RT @sitcancer: New #JITC Research: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and…
New #JITC Research: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations https://t.co/GYaYSPn5Xb https://t.co/UlTmDk0JIf